Loading your page…

Marketing-authorisation holder

Formycon AG

16 medicines5 countries

16 medicines in 5 countries, as authorisation holder.

Its medicines

Group structure

Part of

FormyconPharmaceutical group

Other companies in the group

Germany1

Formycon

Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.

Medicines

Every medicine in the registers under its name, current ones first.

16 medicines

Medicine	Substance	Country	Status	Authorised
AHZANTIVESoluzione iniettabile	Aflibercept	Italy	Authorised
Ahzantive2mg/0.05ml · Injection	Aflibercept	United States	Marketed	2025
Ahzantive	Aflibercept	EU (EMA)	Authorised	2025
AHZANTIVE2mg(0.05ml of 40mg/ml) · Injectable	Aflibercept	United States	Marketed	2024
Ahzantive 40 mg/ml oplossing voor injectie in een injectieflaconOplossing voor injectie	Aflibercept	Netherlands	Authorised	2025
AHZANTIVE 40 MG/ML SOLUCION INYECTABLE EN JERINGA PRECARGADA6,60 mg · Solución inyectable en jeringa precargada	Aflibercept	Spain	Marketed	2025
Baiama	Aflibercept	EU (EMA)	Authorised	2025
BAIAMASoluzione iniettabile	Aflibercept	Italy	Authorised
Baiama 40 mg/ml oplossing voor injectie in een injectieflaconOplossing voor injectie	Aflibercept	Netherlands	Authorised	2025
BAIAMA 40 MG/ML SOLUCION INYECTABLE EN JERINGA PRECARGADA6,6 mg · Solución inyectable en jeringa precargada	Aflibercept	Spain	Marketed	2025
Fymskina	Ustekinumab	EU (EMA)	Authorised	2024
FYMSKINASoluzione iniettabile in siringa pre-riempita	Ustekinumab	Italy	Authorised
Fymskina 130 mg concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie	Ustekinumab	Netherlands	Authorised	2024
Fymskina 45 mg oplossing voor injectie in een voorgevulde spuitOplossing voor injectie	Ustekinumab	Netherlands	Authorised	2024
Fymskina 90 mg oplossing voor injectie in een voorgevulde spuitOplossing voor injectie	Ustekinumab	Netherlands	Authorised	2024
NUFYMCO10mg/ml \| 6mg/ml · Injection	Ranibizumab	United States	Marketed	2025

Sources and licences

Country	Medicines	Current	Companies
Netherlands	5	5	Companies All medicines
European Union (EMA)	3	3	Companies All medicines
Italy	3	3	Companies All medicines
United States	3	3	Companies All medicines
Spain	2	2	Companies All medicines

Compiled by Prognia from the public medicine and company registers below. Logos are not used.

European Medicines Agency

Source: European Medicines Agency (EPAR data).

Licence: EMA reuse policy (source acknowledgement required)

Agencia Española de Medicamentos y Productos Sanitarios (CIMA)

Fuente de la información: AEMPS (CIMA).

Licence: AEMPS open data reuse with attribution

U.S. Food and Drug Administration (Drugs@FDA, openFDA)

Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.

Licence: Public domain (U.S. Government work)

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required

Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom

Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.

All 10 sources

Agenzia Italiana del Farmaco (AIFA), Italy

Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.

Licence: CC BY 4.0; AIFA published open-data catalog

Agenzia Italiana del Farmaco (AIFA), Italy

Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.

Licence: CC BY 4.0; AIFA published open-data catalog

College ter Beoordeling van Geneesmiddelen

College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.

Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim

U.S. Food and Drug Administration

FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.

Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions

Report an error or request removalCorrections from the company itself are welcome.

Formycon AG

Group structure

Part of

Other companies in the group

Germany1

Medicines

Know your medicines, with the sources.

Formycon AG

Group structure

Part of

Other companies in the group

Germany1

Medicines

Know your medicines, with the sources.

Countries

Therapeutic areas

Top substances

Names in the registers

Sources and licences

At a glance

Group structure

Part of

Other companies in the group

🇩🇪Germany1

Medicines

Know your medicines, with the sources.

Group structure

Part of

Other companies in the group

🇩🇪Germany1

Medicines

Know your medicines, with the sources.

Countries

Therapeutic areas

Top substances

Names in the registers

Sources and licences

At a glance

Germany1

Germany1